Advertisement

Medical Oncology

, Volume 27, Issue 3, pp 680–684 | Cite as

The efficacy and safety of reduced-dose docetaxel, cisplatin, and 5-fluorouracil in the first-line treatment of advanced stage gastric adenocarcinoma

  • Nuriye Yıldırım Özdemir
  • Hüseyin AbalıEmail author
  • Berna Öksüzoğlu
  • Burçin Budakoglu
  • Doğan Uncu
  • Tunç Güler
  • Hatice Odabaşı
  • Nurullah Zengin
Original Paper

Abstract

Patients with advanced gastric carcinoma have still had bad prognosis despite advances in the modern treatment era. Docetaxel, cisplatin, 5-fluorouracil (DCF) is effective, but highly toxic regimen for advanced cases. In this study, we modified the standard doses of DCF (mDCF) to evaluate the effectiveness and side effects. From July 2005 to July 2008, 37 advanced gastric cancer patients treated with at least one course of mDCF protocol as first-line treatment were included. The mDCF protocol included 60 mg/m2 docetaxel and cisplatin for 1 day and 600 mg/m2/day, 5-flourouracil infusion for 5 days, repeated every 3 weeks. No patients used prophylactic granulocte -colony stimulating factor. Of the patients, 28 were male and nine were female; the median age was 53 (23–65) years. Of them, 83.8% received at least four courses of chemotherapy and 64.9% completed the preplanned six courses of treatment. Eleven (29.7%) of those patients who received mDCF in the first-line treatment used the FOLFIRI (5-FU, folinic acit, irinotekan) regimen for the second-line treatment. Response rates were evaluated according to RECIST criteria in 30 out of 37 patients. The median follow-up time was 7.1 months. The longest follow-up time was 19.9 months. Two patients (5.4%) had complete response, nine (21.6%) had partial response, and 14 (37.9%) had stabilized disease; overall, the disease was controlled in 25 patients (64.9%) whereas five patients (13.5%) had progression. Median time to progression was 6.7 months and overall survival was 10 months. The assessment of patients for grade 3–4 toxicity revealed that while 5.4% had anemia and 8.1% had neutropenia, 5.4% nausea and 5.4% diarrhea. Neutropenic fever developed in two patients, requiring hospitalization. G-CSF was used in three patients. Two patients with neutropenic fever and two with severe anemia (total number 4; 10.8%) received delayed chemotherapy. Dose reduction was required in four patients (10.8%), one due to neutropenia, one due to nephrotoxicity, and two due to nausea. No patient died due to chemotherapy toxicity. This retrospective study suggested that mDCF might have comparable efficacy with classical DFC, with better toxicity profile. However, its small size and retrospective nature should be considered when interpreting the results.

Keywords

Advanced gastric cancer Docetaxel Cisplatin Fluorouracil Modified 

References

  1. 1.
    Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006;24:2137–50.CrossRefPubMedGoogle Scholar
  2. 2.
    Fuchs CS, Mayer RJ. Gastric carcinoma. N Engl J Med. 1995;333:32–41.CrossRefPubMedGoogle Scholar
  3. 3.
    Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer. 1995;71:587–91.PubMedGoogle Scholar
  4. 4.
    Murad AM, et al. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer. 1993;72:37–41.CrossRefPubMedGoogle Scholar
  5. 5.
    Glimelius B, et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol. 1997;8:163–8.CrossRefPubMedGoogle Scholar
  6. 6.
    Wagner AD, et al. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol. 2006;24:2903–9.CrossRefPubMedGoogle Scholar
  7. 7.
    Preusser P, et al. Phase II study with the combination etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer. J Clin Oncol. 1989;7:1310–7.PubMedGoogle Scholar
  8. 8.
    Lerner A, Gonin R, Steele GD, Mayer RJ. Etoposide, doxorubicin, and cisplatin chemotherapy for advanced gastric adenocarcinoma: results of a phase II trial. J Clin Oncol. 1992;10:536–40.PubMedGoogle Scholar
  9. 9.
    Webb A, et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol. 1997;15:261–7.PubMedGoogle Scholar
  10. 10.
    Kohne CH, et al. Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952. J Clin Oncol. 2003;21:3721–8.CrossRefPubMedGoogle Scholar
  11. 11.
    Ohtsu A, et al. Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol. 2003;21:54–9.CrossRefPubMedGoogle Scholar
  12. 12.
    Cullinan SA, et al. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs. fluorouracil and doxorubicin vs. fluorouracil, doxorubicin, and mitomycin. JAMA. 1985;253:2061–7.CrossRefPubMedGoogle Scholar
  13. 13.
    Koizumi W, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9:215–21.CrossRefPubMedGoogle Scholar
  14. 14.
    Vanhoefer U, et al. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol. 2000;18:2648–57.PubMedGoogle Scholar
  15. 15.
    Muro K, et al. A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer. Ann Oncol. 2004;15:955–9.CrossRefPubMedGoogle Scholar
  16. 16.
    Ajani JA, et al. CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: results of a phase II study. Cancer. 2002;94:641–6.CrossRefPubMedGoogle Scholar
  17. 17.
    Ohtsu A, et al. An early phase II study of a 3-hour infusion of paclitaxel for advanced gastric cancer. Am J Clin Oncol. 1998;21:416–9.CrossRefPubMedGoogle Scholar
  18. 18.
    Van Cutsem E, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006;24:4991–7.CrossRefPubMedGoogle Scholar
  19. 19.
    Roth AD, et al. Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research. J Clin Oncol. 2007;25:3217–23.CrossRefPubMedGoogle Scholar

Copyright information

© Humana Press Inc. 2009

Authors and Affiliations

  • Nuriye Yıldırım Özdemir
    • 1
  • Hüseyin Abalı
    • 2
    • 4
    Email author
  • Berna Öksüzoğlu
    • 1
  • Burçin Budakoglu
    • 3
  • Doğan Uncu
    • 1
  • Tunç Güler
    • 1
  • Hatice Odabaşı
    • 1
  • Nurullah Zengin
    • 1
  1. 1.Medical Oncology ClinicMinistry of Health Ankara Research and Training HospitalAnkaraTurkey
  2. 2.Medical Oncology Unit Baskent University Faculty of MedicineAnkaraTurkey
  3. 3.Medical Oncology ClinicMinistry of Health Abdurrahman Dr Yurtaslan Oncology Research and Training HospitalAnkaraTurkey
  4. 4.Adana Uygulama ve Araştırma MerkeziBaşkent Üniversitesi Tıp FakültesiYüreğir-AdanaTurkey

Personalised recommendations